Botanix Pharmaceuticals shares rose four per cent yesterday on news it had completed a Phase 2a study into the use of CBD as an anti-microbial agent for staph infections.
The company’s BTX 1801 treatment, which received US FDA approval in April this year, has Qualified Infectious Disease Product (QIDP) status and is being developed to reduce infections in post-surgical patients.
Botanix now needs to put the product through trials in order to bring it to market, hence the Phase 2a study. The participating patients have been treated with BTX 1801 and this will determine the final data points and ultimate results.
The company said the results could be available as early as Q1 next year.
Of the new treatment, Botanix president and executive chairman Vince Ippolito said: “There has not been a new class of antibiotic for the treatment of gram-positive bacteria in more than 30 years and serious staph and MRSA infections have become very difficult to treat.
“The company has worked diligently to complete the BTX 1801 Phase 2a study despite the significant disruption caused by the COVID-19 pandemic.”
“We look forward to updating the market once top-line data is available early in the new year.”
